Lung cancer

EA5181

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable

Trial overview

Topic

EA5181

Disease

Lung cancer treatment and diagnosis

Description

Primary Objective:The primary objective of the trial is to determine whether concurrent MEDI4736 (durvalumab) with cytoxic chemo/radiation improves overall survival (OS) in addition to a standard therapy (chemotherapy and radiation followed by consolidative MEDI4736 (durvalumab)). Secondary objectives include estimation of progression-free survival, best objective response, incidence of local/distant progression, and toxicity.Patient Population:Patients with unresectable Stage 3 Non-small cell lung cancer.

Contact

Michigan

Maria Pappas

Contact

Florida

Peggy Mouradian

Physicians

Thomas Boike

MD

Radiation Oncologist

Clarkston (Radiation oncology) +3

Larry L. Kestin

MD, FACR, FASTRO

Radiation Oncologist

Farmington Hills (Radiation oncology) +2

Alvaro A. Martinez

MD, FACR, FABS, FASTRO

Radiation Oncologist

Pontiac (Radiation oncology) +4

Frank A. Vicini

MD, FACR, FASTRO, FABS

Radiation Oncologist

Farmington Hills (Radiation oncology) +2

John Vito Antonucci

MD

Radiation Oncologist

Madison Heights (Radiation oncology) +3

Michael I. Ghilezan

MD, PhD

Radiation Oncologist

Pontiac (Radiation oncology) +3

Eduardo B. Fernandez

MD, PhD, DABR, FACRO, FASTRO

Radiation Oncologist

Aventura (Radiation oncology) +3

Christopher T. Chen

MD, FACRO

Radiation Oncologist

Pembroke Pines (Radiation oncology) +2